The serotonin transporter (SERT) is the molecular target for most antidepressant drugs as well as many drugs of abuse. Antidepressants such as paroxetine, fluoxetine, and imipramine bind to the transporter and inhibit serotonin uptake, thereby prolonging the extracellular lifespan of the neurotransmitter. The abused psychostimulants cocaine and amphetamine also bind to the transporter, but have distinct pharmacologic effects leading to abuse potential and possible neurotoxicity. Despite the cloning of SERT in the early 1990's, very little information is available regarding the molecular and cellular neurobiology surrounding the function of this transport protein. This project uses a multidisciplinary approach aimed at significantly advancing knowledge regarding the molecular pharmacology of psychostimulants at SERTs. The studies will use multiple techniques including expression and characterization of recombinant transporters in mammalian cells, electrophysiology, immunoblotting, the formation of chimeric proteins, and site- directed mutagenesis to identify amino acids involved with specific transporter functions including antagonist and substrate binding. In addition, computer-assisted structure-activity studies of cocaine and amphetamine derivatives will be coupled with mutagenesis in an attempt to identify direct ligand- transporter interactions. Therefore, the specific aims of this project are 1) to identify transporter domains and residues involved in recognition of SERT antagonists such as cocaine and 2) to determine the contributions of specific SERT domains to substrate properties such as translocation, efflux, and channel- like activity. The proposed strategies will provide critical new information linking protein structure to functional properties of the transporter and an enhanced understanding of the molecular mechanisms of action for psychotherapeutic and abused drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
1R01MH060221-01A1
Application #
6197542
Study Section
Special Emphasis Panel (ZRG1-MDCN-4 (01))
Program Officer
Brady, Linda S
Project Start
2000-09-01
Project End
2004-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
1
Fiscal Year
2000
Total Cost
$211,256
Indirect Cost
Name
Purdue University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
072051394
City
West Lafayette
State
IN
Country
United States
Zip Code
47907
Ashtari, Manzar; Cervellione, Kelly L; Hasan, Khader M et al. (2007) White matter development during late adolescence in healthy males: a cross-sectional diffusion tensor imaging study. Neuroimage 35:501-10
Gallardo-Godoy, Alejandra; Torres-Altoro, Melissa I; White, Kellie J et al. (2007) 1-Methylpyridinium-4-(4-phenylmethanethiosulfonate) iodide, MTS-MPP+, a novel scanning cysteine accessibility method (SCAM) reagent for monoamine transporter studies. Bioorg Med Chem 15:305-11
White, Kellie J; Kiser, Philip D; Nichols, David E et al. (2006) Engineered zinc-binding sites confirm proximity and orientation of transmembrane helices I and III in the human serotonin transporter. Protein Sci 15:2411-22
Kester, Hana M; Sevy, Serge; Yechiam, Eldad et al. (2006) Decision-making impairments in adolescents with early-onset schizophrenia. Schizophr Res 85:113-23
Thaden, Emily; Rhinewine, Joseph P; Lencz, Todd et al. (2006) Early-onset schizophrenia is associated with impaired adolescent development of attentional capacity using the identical pairs continuous performance test. Schizophr Res 81:157-66
Kranzler, Harvey; Roofeh, David; Gerbino-Rosen, Ginny et al. (2005) Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 44:55-63
Gerbino-Rosen, Ginny; Roofeh, David; Tompkins, D Andrew et al. (2005) Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry 44:1024-31
Rhinewine, Joseph P; Lencz, Todd; Thaden, Emily P et al. (2005) Neurocognitive profile in adolescents with early-onset schizophrenia: clinical correlates. Biol Psychiatry 58:705-12
Kumra, Sanjiv; Ashtari, Manzar; McMeniman, Marjorie et al. (2004) Reduced frontal white matter integrity in early-onset schizophrenia: a preliminary study. Biol Psychiatry 55:1138-45
Roman, David L; Saldana, Shannon N; Nichols, David E et al. (2004) Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters. J Pharmacol Exp Ther 308:679-87

Showing the most recent 10 out of 11 publications